Human/chicken urokinase chimeras demonstrate sequences outside the serine protease domain that dictate autoactivation

Thrombosis and Haemostasis

Volumn 89, Issue 2, 2003, Pages 382-392

  Aimes, Ronald T ^a   Regazzoni, Karine ^a   Quigley, James P ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Autoactivation; Mutagenesis; Serine protease; Urokinase; Zymogen

Indexed keywords

ENZYME PRECURSOR; PLASMIN; POLYPEPTIDE; SARUPLASE; SERINE PROTEINASE; UROKINASE;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; CATALYSIS; CHICKEN; CHIMERA; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVE SITE; ENZYME MECHANISM; ENZYME SPECIFICITY; ENZYME STABILITY; HUMAN; HUMAN CELL; MAMMAL; MUTAGENESIS; MUTANT; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEGRADATION;

EID: 0037329659     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1613456     Document Type: Article

References (36)

1. Irigoyen JP, Munoz-Canoves P, Montero L, Koziczak M, Nagamine Y. The plasminogen activator system: Biology and regulation. Cell Mol Life Sci 1999; 56: 104-32.
2. Kasai S, Arimura H, Nishida M, Suyama T. Primary structure of single-chain pro-urokinase. J Biol Chem 1985; 260: 12382-9.
3. Pannell R, Gurewich V. Activation of plasminogen by single-chain urokinase or by two-chain urokinase - A demonstration that single-chain urokinase has a low catalytic activity (pro-urokinase). Blood 1987; 69: 22-6.
4. 158 → Glu). J Biol Chem 1990; 265: 5232-6.
5. Petersen LC, Lund LR, Nielsen LS, Dano K, Skriver L. One-chain urokinase-type plasminogen activator from human sarcoma cells is a proenzyme from human sarcoma cells is a proenzyme with little or no intrinsic activity. J Biol Chem 1988; 263: 11189-95.
6. Bugge TH, Flick MJ, Daugherty CC, Degen JL. Plasminogen deficiency causes severe thrombosis but is compatible with development and reproduction. Genes Dev 1995; 9: 794-807.
7. Lee SL, Dickson RB, Lin CY. Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease. J Biol Chem 2000; 275: 36720-5.
8. Takeuchi T, Harris JL, Huang W, Yan KW, Coughlin SR, Craik CS. Cellular localization of membrane-type serine protease 1 and identification of protease-activated receptor-2 and single-chain urokinase-type plasminogen activator as substrates. J Biol Chem 2000; 275: 26333-42.
9. List K, Jensen ON, Bugge TH, Lund LR, Plou M, Dano K, et al. Plasminogen-independent initiation of the pro-urokinase activation cascade in vivo. Activation of pro-urokinase by glandular kallikrein (mGK-6) in plasminogen-deficient mice. Biochemistry 2000; 39: 508-15.
10. Higazi A, Cohen RL, Henkin J, Kniss D, Schwartz BS, Cines DB. Enhancement of the enzymatic activity of single-chain urokinase plasminogen activator by soluble urokinase receptor. J Biol Chem 1995; 270: 17375-80.
11. Manchanda N, Schwartz BS. Single chain urokinase. Augmentation of enzymatic activity upon binding to monocytes. J Biol Chem 1991; 266: 14580-4.
12. Leslie ND, Kessler CA, Bell SM, Degen JL. The chicken urokinase-type plasminogen activator gene. J Biol Chem 1990; 265: 1339-44.
13. Alexander DS, Sipley JD, Quigley JP. Autoactivation of avian urokinase-type plasminogen activator (uPA). A novel mode of initiation of the uPA/plasmin cascade. J Biol Chem 1998; 273: 7457-61.
14. Sipley JD, Alexander DS, Testa JE, Quigley JP. Introduction of an RRHR motif into chicken urokinase-type plasminogen activator (ch-uPA) confers sensitivity to plasminogen activator inhibitor (PAI)-1 and PAI-2 and allows ch-uPA-mediated extracellular matrix degradation to be controlled by PAI-1. Proc Natl Acad Sci USA 1997; 94: 2933-8.
15. Bebbington CR, Renner G, Thomson S, King D, Abrams D, Yarranton GT. High-level expression of a recombinant antibody from myeloma cells using a glutamine synthetase gene as amplifiable selectable marker. Bio/Technology 1992; 10: 169-75.
16. Berkenpas MB, Quigley JP. Transformation-dependent activation of urokinase-type plasminogen activator by a plasmin-independent mechanism: Involvement of cell surface membranes. Proc Natl Acad Sci USA 1991; 88: 7768-72.
17. Stump DC, Thienpont M, Collen D. Urokinase-related proteins in human urine. Isolation and characterization of single-chain urokinase (pro-urokinase) and urokinase-inhibitor complex. J Biol Chem 1986; 261: 1267-73.
18. Matsudaira P. Sequence from picomole quantities of proteins electroblotted onto polyvinylidene difluoride membranes. J Biol Chem 1987; 262: 10035-8.
19. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-5.
20. Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: Procedures and some applications. Proc Natl Acad Sci USA 1979; 76: 4350-4.
21. Fussi F. Aprotinin: Mechanism of action and therapeutical uses. Boll Chim Farm 1980; 119: 631-46.
22. Nelles L, Lijnen HR, Collen D, Holmes WE. Characterization of recombinant human single chain urokinase-type plasminogen activator mutants produced by site-specific mutagenesis of lysine 158. J Biol Chem 1987; 262: 5682-9.
23. Gunzler WA, Steffens GJ, Otting F, Kim SM, Frankus E, Flohe L. The primary structure of high molecular mass urokinase from human urine. The complete amino acid sequence of the A chain. Hoppe Seylers Z Physiol Chem 1982; 363: 1155-65.
24. Ellis V, Scully MF, Kakkar VV. Plasminogen activation initiated by single-chain urokinase-type plasminogen activator. Potentiation by U937 monocytes. J Biol Chem 1989; 264: 2185-8.
25. Stephens RW, Pollanen J, Tapiovaara H, et al. Activation of pro-urokinase and plasminogen on human sarcoma cells: A proteolytic system with surface-bound reactants. J Cell Biol 1989; 108: 1987-95.
26. Andreasen PA, Kjøller L, Christensen L, Duffy MJ. The urokinase-type plasminogen activator system in cancer metastasis: A review. Int J Cancer 1997; 72: 1-22.
27. Higazi AA, Mazar A, Wang J, Reilly R, Henkin J, Kniss D et al. Single-chain urokinase-type plasminogen activator bound to its receptor is relatively resistant to plasminogen activator inhibitor type 1. Blood 1996; 87: 3545-9.
28. Hooper JD, Clements JA, Quigley JP, Antalis TM. Type II transmembrane serine proteases. Insights into an emerging class of cell surface proteolytic enzymes. J Biol Chem 2001; 276: 857-60.
29. Kannemeier C, Feussner A, Stohr HA, Weisse J, Preissner KT, Romisch J. Factor VII and single-chain plasminogen activator-activating protease: Activation and autoactivation of the proenzyme. Eur J Biochem 2001; 268: 3789-96.
30. Etscheid M, Hunfeld A, Konig H, Seitz R, Dodt J. Activation of proPHBSP, the zymogen of a plasma hyaluronan binding serine protease, by an intermolecular autocatalytic mechanism. Biol Chem 2000; 381: 1223-31.
31. Denmeade SR, Lovgren J, Khan SR, Lilja H, Isaacs JT. Activation of latent protease function of pro-hK2, but not pro-PSA, involves autoprocessing. Prostate 2001; 48: 122-6.
32. Donate F, Kelly CR, Ruf W, Edgington TS. Dimerization of tissue factor supports solution-phase autoactivation of factor VII without influencing proteolytic activation of factor X. Biochemistry 2000; 39: 11467-76.
33. Kowalska-Loth B, Zakrzewski K. The activation by staphylokinase of human plasminogen. Acta Biochim Pol 1975; 22: 327-39.
34. Wang S, Reed GL, Hedstrom L. Zymogen activation in the streptokinase-plasminogen complex. Ile1 is required for the formation of a functional active site. Eur J Biochem 2000; 267: 3994-4001.
35. Sazonova IY, Houng AK, Chowdhry SA, Robinson BR, Hedstrom L, Reed GL. The mechanism of a bacterial plasminogen activator intermediate between streptokinase and staphylokinase. J Biol Chem 2001; 276: 12609-13.
36. Testa JE, Stefansson S, Sioussat T, Quigley JP. Avian urokinase-type plasminogen activator (u-PA) lacks the putative binding site for plasminogen activator inhibitor (PAI) and is resistant to inhibition by human PAI-1 and PAI-2. Fibrinolysis 1995; 9: 93-9.